Cardiff Oncology (CRDF)
(Real Time Quote from BATS)
$2.58 USD
+0.07 (2.79%)
Updated Aug 5, 2025 09:58 AM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRDF 2.58 +0.07(2.79%)
Will CRDF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRDF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRDF
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates
Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know
CRDF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?
Other News for CRDF
Video: Friday 8/1 Insider Buying Report: CRDF, MBIN
Largest borrow rate increases among liquid names
12 Health Care Stocks Moving In Wednesday's Intraday Session
Cardiff Oncology: Data Update Resolves Some Signals
12 Health Care Stocks Moving In Wednesday's Pre-Market Session